Arcus Biosciences, Inc. RCUS
18.67 USD 0.00 (+0.00%)
At closeNov 11, 2026, 9:09 AM EST
18.93 +0.26 +1.39%
Pre-market · Nov 11, 9:09 AM ET
Day range unavailable
17.43 52-week range 31.74
- YTD
- -21.65%
- 1 year
- -4.06%
News
benzinga.com Leerink Partners Maintains Outperform on Arcus Biosciences, Raises Price Target to $49 Leerink Partners analyst Daina Graybosch maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $46 to $49.
benzinga.com Truist Securities Maintains Buy on Arcus Biosciences, Lowers Price Target to $40 Truist Securities analyst Supawat Thongthip maintains Arcus Biosciences (NYSE:RCUS) with a Buy and lowers the price target from $41 to $40.
benzinga.com Wedbush Maintains Outperform on Arcus Biosciences, Lowers Price Target to $45 Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and lowers the price target from $49 to $45.
zacks.com Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Lags Revenue Estimates Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.27 per share a year ago.
benzinga.com Arcus Biosciences Q3 EPS $(1.00) Misses $(0.90) Estimate, Sales $9.000M Beat $8.305M Estimate Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of $(0.90) by 11.11 percent. This is a 21.26 percent increase over losses of…
businesswire.com Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares increased by 232.0% to $2.0 during Monday's pre-market session. The company's market cap stands at $62.2 million. AngioDynamics (NASDAQ:ANGO) shares…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Tempest Therapeutics (NASDAQ:TPST) stock rose 8.9% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $10.1 million. Tenax Therapeutics…- benzinga.com Arcus Biosciences Commences Public Offering of Common Stock; Size Not Disclosed Arcus Biosciences, Inc. (NYSE:RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune…
benzinga.com Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $50 Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $45 to $50.- benzinga.com Truist Securities Maintains Buy on Arcus Biosciences, Raises Price Target to $41 Truist Securities analyst Supawat Thongthip maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $40 to $41.
benzinga.com Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $49 Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $43 to $49.
benzinga.com Arcus Biosciences Reports Casdatifan Kidney Cancer Data, With Nearly 3-Year Median Overall Survival In Heavily Pretreated Patients And Phase 3 Trials Remain Pending Progression-free survival (PFS) for casdatifan plus anti-PD-1 in the first-line (1L) setting exceeded third-party benchmarks* for the approved anti-PD-1 plus anti-CTLA-4 regimen (ipilimumab plus…- benzinga.com William Blair Initiates Coverage On Arcus Biosciences with Outperform Rating William Blair analyst Alethia Young initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Outperform rating.
- benzinga.com JP Morgan Initiates Coverage On Arcus Biosciences with Overweight Rating, Announces Price Target of $41 JP Morgan analyst Priyanka Grover initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Overweight rating and announces Price Target of $41.
- benzinga.com Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $43 Price Target Wedbush analyst Robert Driscoll reiterates Arcus Biosciences (NYSE:RCUS) with a Outperform and maintains $43 price target.
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday's pre-market session. The company's market cap stands at $1.1 million. Definium Therapeutics…
- benzinga.com Truist Securities Reiterates Buy on Arcus Biosciences, Raises Price Target to $40 Truist Securities analyst Supawat Thongthip reiterates Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $35 to $40.
- benzinga.com Wells Fargo Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $26 Wells Fargo analyst Eva Fortea Verdejo maintains Arcus Biosciences (NYSE:RCUS) with a Equal-Weight and raises the price target from $23 to $26.
- benzinga.com Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $43 Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $41 to $43.
- benzinga.com Arcus Biosciences Q2 EPS $(0.72) Beats $(0.87) Estimate, Sales $41.000M Beat $23.405M Estimate Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.87) by 17.24 percent. This is a Infinity percent decrease over earnings…
benzinga.com Arcus Biosciences Announces A Clinical Supply Agreement With AVEO Oncology To Evaluate Casdatifan; Agreement Supports A New Randomized Cohort Within The ARC-20 Study Evaluating Investigational Casdatifan Plus Tivozanib Versus Tivozanib Alone In Patients Who Received Prior HIF-2α-inhibitor Therapy; Enrollment Expected To Begin In Q4 2026 This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor…- benzinga.com Arcus Biosciences And Summit Therapeutics Announced A Clinical Trial Collaboration To Evaluate The Safety And Efficacy Of Arcus’s Casdatifan; Data Expected to Be Generated By Mid-2027 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and…
benzinga.com Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%? HC Wainwright lifted Arcus Biosciences' price target, citing broader revenue potential for casdatifan in first-line ccRCC.- benzinga.com HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $45 HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $32 to $45.
- benzinga.com Arcus Biosciences Announces Publication In Nature Describing New Research From The ARC-20 Study Showing Casdatifan HIF-2a Inhibition Deeply Suppresses Serum EPO And Extends Progression-Free Survival In Advanced Kidney Cancer This is the first study to comprehensively interconnect clinical outcomes from patients receiving a HIF-2a inhibitor with peripheral biomarker changes and associated tumor biologyHIF-2a inhibition…
- benzinga.com Arcus Biosciences Enters Clinical Trial Collaboration And Supply Agreement With Bristol Myers Squibb; Will Supply Casdatifan, Its Investigational Small-Molecule HIF-2a Inhibitor Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and…
- benzinga.com Truist Securities Assumes Arcus Biosciences at Buy, Raises Price Target to $35 Truist Securities analyst Supawat Thongthip assumes Arcus Biosciences (NYSE:RCUS) with a Buy rating and raises Price Target to $35.
- benzinga.com Morgan Stanley Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $22 Morgan Stanley analyst Terence Flynn maintains Arcus Biosciences (NYSE:RCUS) with a Equal-Weight and raises the price target from $20 to $22.
- benzinga.com Goldman Sachs Maintains Buy on Arcus Biosciences, Raises Price Target to $34 Goldman Sachs analyst Richard Law maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $30 to $34.
- benzinga.com Arcus Biosciences Q1 EPS $(1.02) Misses $(0.93) Estimate, Sales $17.000M Miss $29.484M Estimate Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(1.02) per share which missed the analyst consensus estimate of $(0.93) by 9.68 percent. This is a 10.53 percent increase over losses of…
benzinga.com Earnings Scheduled For May 5, 2026 
benzinga.com What's Going On With Arcus Biosciences Stock On Wednesday? Arcus Biosciences halts STAR-121 lung cancer trial after futility review while Gilead Science declines option extension.- benzinga.com Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $41 Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $37 to $41.
- benzinga.com Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $45 Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $44 to $45.
- benzinga.com Leerink Partners Maintains Outperform on Arcus Biosciences, Raises Price Target to $49 Leerink Partners analyst Geoffrey Porges maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $36 to $49.
benzinga.com The Analyst Verdict: Arcus Biosciences In The Eyes Of 5 Experts - benzinga.com HC Wainwright & Co. Reiterates Buy on Arcus Biosciences, Maintains $32 Price Target HC Wainwright & Co. analyst Emily Bodnar reiterates Arcus Biosciences (NYSE:RCUS) with a Buy and maintains $32 price target.
benzinga.com Arcus Biosciences Earnings Review: Q4 Summary 
benzinga.com Arcus Biosciences Q4 EPS $(0.89) Beats $(1.03) Estimate, Sales $33.000M Miss $35.711M Estimate Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.89) per share which beat the analyst consensus estimate of $(1.03) by 13.51 percent. This is a 13.59 percent increase over losses of…- benzinga.com Earnings Scheduled For February 25, 2026
benzinga.com This Inspire Medical Systems Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday 
benzinga.com What Analysts Are Saying About Arcus Biosciences Stock - benzinga.com Wells Fargo Downgrades Arcus Biosciences to Equal-Weight, Lowers Price Target to $23 Wells Fargo analyst Eva Fortea Verdejo downgrades Arcus Biosciences (NYSE:RCUS) from Overweight to Equal-Weight and lowers the price target from $30 to $23.
- benzinga.com Goldman Sachs Upgrades Arcus Biosciences to Buy, Raises Price Target to $28 Goldman Sachs analyst Richard Law upgrades Arcus Biosciences (NYSE:RCUS) from Neutral to Buy and raises the price target from $16 to $28.
- benzinga.com Morgan Stanley Downgrades Arcus Biosciences to Equal-Weight, Lowers Price Target to $20 Morgan Stanley analyst Terence Flynn downgrades Arcus Biosciences (NYSE:RCUS) from Overweight to Equal-Weight and lowers the price target from $23 to $20.
benzinga.com Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan, supported by strong early RCC data and key 2026 milestones.- benzinga.com HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $32 HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $28 to $32.
- benzinga.com Arcus Biosciences Discontinues Phase 3 STAR-221 Study With Gilead Following IDMC Futility Recommendation The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futilityArcus is continuing to expand its development program for…
benzinga.com B of A Securities Maintains Neutral on Arcus Biosciences, Raises Price Target to $26 B of A Securities analyst Jason Zemansky maintains Arcus Biosciences (NYSE:RCUS) with a Neutral and raises the price target from $17 to $26.